C225-ILS-DOX

N/A

Report date: 2024/11/15 17:00:34

Base Information

Drug NameC225-ILS-DOX
Drug Alias NameC225-ILs-dox
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsTopoisomerase II inhibitors
TargetsTopoisomerase IIEpidermal growth factor receptor erbB1
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversitaetsspitals Basel
China Registration ClassN/A

Develop Information

Active CompaniesUniversitaetsspitals Basel
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A